ERAS vs DBVT vs IMVT vs MRK

Merck & Co.

, Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 9x forward), making it the more compelling value choice. Analysts rate Erasca, Inc. (ERAS) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Merck & Co.

, Inc. (MRK) delivered a total return of +70. 2%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 48β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 189% more volatile than MRK relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 96% for Merck & Co. , Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Erasca, Inc.

grew EPS 16. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — MRK leads at 72. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

In this comparison, MRK (2.

9% yield) pays a dividend. ERAS, DBVT, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48), 2. 9% yield, +166. 5% 10Y return). Both have compounded well over 10 years (MRK: +166. 5%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ERAS is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; IMVT is a small-cap quality compounder stock; MRK is a large-cap deep-value stock. MRK pays a dividend while ERAS, DBVT, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.